---
run_id: halo-evidence-vs-diagnosis-validation-v12-generic-advice-prompted-05
created: 2026-05-24
eval_type: contradiction-preservation
case_id: halo-evidence-vs-diagnosis-validation-v12
benchmark_version: halo-evidence-vs-diagnosis-validation-v12-v1
model_condition: generic_advice_prompted
run_number: 5
model_name: gemma-4-31b-it-mlx:2
model_id: gemma-4-31b-it-mlx:2
model_snapshot: LM Studio MLX 8-bit model id lmstudio-community/gemma-4-31B-it-MLX-8bit; loaded_context_length 65536
runtime: LM Studio local OpenAI-compatible HTTP server; MLX runtime
provider: local
temperature: 0.7
top_p: 0.9
num_ctx: 65536
max_tokens: 2048
seed: 505
prompt_source: condition packet (generic_advice_prompted) - frozen added material plus frozen Advisor prompt; see run-packet.md
prompt_sha256: 81621976eaf302301d88434e895bffe7f264ddbe9d86bbb0dd82120c2f65f2aa
source_packet: a short generic advice-quality request, then the frozen Advisor prompt; no rubric and no sources - see run-packet.md
source_packet_sha256: 2d3cd0a66ac65ac18e241525d58fddd7447998bf4d887a6f8c7bfef16372a25d
condition_packet_sha256: 2d3cd0a66ac65ac18e241525d58fddd7447998bf4d887a6f8c7bfef16372a25d
output_file: model-outputs/generic_advice_prompted-05.md
judge_model_id: pending - judge receipts recorded separately under judge-packet
judge_prompt_sha256: pending - judge receipts recorded separately under judge-packet
judge_independence: pending - judge receipts recorded separately under judge-packet
raw_model_output_public_safe: true
---

# Model Output - generic_advice_prompted (run 05)

## Condition

Benchmark version `halo-evidence-vs-diagnosis-validation-v12-v1`, condition `generic_advice_prompted`, run 5 of 8. Real local-model run: `gemma-4-31b-it-mlx:2` via lmstudio, seed 505, on the frozen condition packet.

## Output

I recommend that you commit to the **Case Evidence Review**.

### Reasoning and Tradeoffs

Your company is currently experiencing a "false positive" signal. The executive team sees growth and alignment, but the underlying data suggests you have a **utility gap**, not a demand problem.

The expansion bookings and shortened sales cycles are likely driven by the "bundle price" (a financial incentive) and the roadmap pitch (selling a vision), rather than the current product's value. The usage data is particularly alarming: managers are using it for "enablement" (training/demos), while the actual practitioners—the analysts—abandon it after two days or cannot justify its output to reviewers.

Here is why the other options are insufficient for this specific crisis:
*   **Scaling Broadly:** This is high-risk. You are seeing early signals of churn from regional administrators. Scaling a product that analysts find "impossible to explain" will accelerate churn once the bundle-pricing honeymoon ends.
*   **Adoption Quality Sprint:** This measures *behavior*, but not *value*. You already know the behavior: analysts use it briefly and then stop. Tracking "return rates" won't tell you *why* they are leaving or how to fix the output.
*   **Demand Cleanroom:** This tests *willingness to pay*, but you already have the answer: customers are buying it when it's discounted or promised as a future roadmap. Testing this now tells you that your pricing is wrong, but it doesn't tell you if the product is broken.
*   **Narrowing to Public Sector:** This is premature and likely a mistake. The public sector has the *most* friction (reviewers demanding explanations), making it the hardest place to start, not the easiest.

The **Case Evidence Review** is the only option that attacks the core uncertainty: *Is PlanPilot actually solving the problem, or are people just pretending to use it because it looks impressive in a demo?* By auditing the "accepted vs. overridden" actions, you move from proxy metrics (usage/bookings) to ground-truth utility.

### The Tradeoff
By choosing the Case Evidence Review, you are sacrificing **immediate commercial validation**. You are essentially telling the CEO and Board that you cannot yet confirm if the recent revenue spike is sustainable. You are choosing a "slow" qualitative truth over a "fast" quantitative metric.

### The Strongest Reason Against This Recommendation
The Case Evidence Review is a lagging indicator and provides a small sample size. In twelve days, the Board wants confidence to fund a growth engine. A qualitative review of case files feels like "product tinkering" compared to the "Demand Cleanroom," which speaks the language of the Board (revenue and intent). There is a risk that while you are reviewing files, the sales team continues to sell a version of the product that doesn't actually work, creating a massive "expectation gap" for next year's renewals.

### Evidence That Would Change My Mind
I would pivot to the **Demand Cleanroom** if you discovered that the "regional administrators" who want to remove PlanPilot are outliers with unique technical constraints, and that national accounts are renewing *specifically* because of the current output quality (not the bundle price). If the "overrides" in the product are actually "refinements" (meaning the AI got them 80% of the way there and they liked it), then the product is healthy, and your only remaining risk is pricing—making the Cleanroom the priority.
